BERTOLINI ROBERT J
Known title: DirectorCIK: 0001270263
Associated companies
Transaction History
| CRL | ▲ Buy | Grant | 559 | $128K | 5/13/2024 | View on chart |
| CRL | ▲ Buy | Grant | 394 | $90K | 5/13/2024 | View on chart |
| CRL | ▲ Buy | Grant | 664 | $0 | 5/15/2023 | View on chart |
| CRL | ▲ Buy | Grant | 468 | $0 | 5/15/2023 | View on chart |
| CRL | ▲ Buy | Grant | 575 | $0 | 5/11/2022 | View on chart |
| CRL | ▲ Buy | Grant | 405 | $0 | 5/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CRL Analyst Targets Rise After UBS Reinstates Coverage
Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.
CRL Analyst Targets Rise After UBS Reinstates Coverage. Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.